 |
|
Relative Risk of Cardiovascular and Cancer Mortality in People With Severe Mental Illness From the United Kingdom's General Practice Research Database
David P. J. Osborn, PhD;
Gus Levy, MSc;
Irwin Nazareth, PhD;
Irene Petersen, PhD;
Amir Islam, MBA;
Michael B. King, PhD
Arch Gen Psychiatry. 2007;64(2):242-249.
Context People with severe mental illness (SMI) appear to have an elevated risk of death from cardiovascular disease, but results regarding cancer mortality are conflicting.
Objective To estimate this excess mortality and the contribution of antipsychotic medication, smoking, and social deprivation.
Design Retrospective cohort study.
Setting United Kingdom's General Practice Research Database.
Patients Two cohorts were compared: people with SMI diagnoses and people without such diagnoses.
Main Outcome Measure Mortality rates for coronary heart disease (CHD), stroke, and the 7 most common cancers in the United Kingdom.
Results A total of 46 136 people with SMI and 300 426 without SMI were selected for the study. Hazard ratios (HRs) for CHD mortality in people with SMI compared with controls were 3.22 (95% confidence interval [CI], 1.99-5.21) for people 18 through 49 years old, 1.86 (95% CI, 1.63-2.12) for those 50 through 75 years old, and 1.05 (95% CI, 0.92-1.19) for those older than 75 years. For stroke deaths, the HRs were 2.53 (95% CI, 0.99-6.47) for those younger than 50 years, 1.89 (95% CI, 1.50-2.38) for those 50 through 75 years old, and 1.34 (95% CI, 1.17-1.54) for those older than 75 years. The only significant result for cancer deaths was an unadjusted HR for respiratory tumors of 1.32 (95% CI, 1.04-1.68) for those 50 to 75 years old, which lost statistical significance after controlling for smoking and social deprivation. Increased HRs for CHD mortality occurred irrespective of sex, SMI diagnosis, or prescription of antipsychotic medication during follow-up. However, a higher prescribed dose of antipsychotics predicted greater risk of mortality from CHD and stroke.
Conclusions This large community sample demonstrates that people with SMI have an increased risk of death from CHD and stroke that is not wholly explained by antipsychotic medication, smoking, or social deprivation scores. Rates of nonrespiratory cancer mortality were not raised. Further research is required concerning prevention of this mortality, including cardiovascular risk assessment, monitoring of antipsychotic medication, and attention to diet and exercise.
Author Affiliations: Department of Mental Health Sciences (Drs Osborn and King and Mr Levy) and Department of Primary Care and Population Sciences (Drs Nazareth and Petersen and Mr Islam), Royal Free and University College Medical School, London, England.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
A survey on takeaways in a secure unit
Kasmi
Psychiatr. Bull. 2009;33:276-277.
FULL TEXT
Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology
Goodwin and Consensus Group of the British Association for Psy
J Psychopharmacol 2009;23:346-388.
ABSTRACT
Health Care for Patients with Serious Mental Illness: Family Medicine's Role
Morden et al.
J Am Board Fam Med 2009;22:187-195.
ABSTRACT
| FULL TEXT
Depression and heart disease: What do we know, and where are we headed?
POZUELO et al.
Cleveland Clinic Journal of Medicine 2009;76:59-70.
ABSTRACT
| FULL TEXT
Psychiatric Hospital Admissions, Behavioral Risk Factors, and All-Cause Mortality: The Scottish Health Survey
Hamer et al.
Arch Intern Med 2008;168:2474-2479.
ABSTRACT
| FULL TEXT
Exposure to antipsychotics and risk of stroke: self controlled case series study
Douglas and Smeeth
BMJ 2008;337:a1227-a1227.
ABSTRACT
| FULL TEXT
Gender Differences in Health-Related Quality of Life for Veterans With Serious Mental Illness
Teh et al.
Psychiatr. Serv. 2008;59:663-669.
ABSTRACT
| FULL TEXT
Influence of 5-HT2C receptor and leptin gene polymorphisms, smoking and drug treatment on metabolic disturbances in patients with schizophrenia
Yevtushenko et al.
Br. J. Psychiatry 2008;192:424-428.
ABSTRACT
| FULL TEXT
Treatment Pathway and Patterns of Clozapine Prescribing for Schizophrenia in New Zealand
Wheeler
The Annals of Pharmacotherapy 2008;42:852-860.
ABSTRACT
| FULL TEXT
Antecedents and Sequelae of Sudden Parental Death in Offspring and Surviving Caregivers
Melhem et al.
Arch Pediatr Adolesc Med 2008;162:403-410.
ABSTRACT
| FULL TEXT
The emerging physical health challenges of antipsychotic associated hyperprolactinaemia in patients with serious mental illness
Dursun et al.
J Psychopharmacol 2008;22:3-5.
The evolution of hyperprolactinaemia as an entity in psychiatric patients
Kohen and Wildgust
J Psychopharmacol 2008;22:6-11.
ABSTRACT
Antipsychotics and hyperprolactinaemia: Clinical recommendations
Peveler et al.
J Psychopharmacol 2008;22:98-103.
Schizophrenia Host Vulnerability and Risk of Metabolic Disturbances During Treatment with Antipsychotics
Buckley et al.
Focus 2008;6:172-179.
ABSTRACT
| FULL TEXT
ANOTHER EXAMPLE OF AN ILLICIT CIGARETTE MARKET: A STUDY OF PSYCHIATRIC PATIENTS IN TORONTO, ONTARIO
Callaghan et al.
Am. J. Public Health 2008;98:4-5.
FULL TEXT
Metabolic disease and cardiovascular risk in people treated with antipsychotics in the community
Mackin et al.
Br. J. Psychiatry 2007;191:23-29.
ABSTRACT
| FULL TEXT
Serious Medical and Psychiatric Illnesses: How Often Are They Comorbid?
JWatch Psychiatry 2007;2007:4-4.
FULL TEXT
|
